Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Xiaomeng Yue, Ana L. Hincapie, Yuxiang Li & Jeff J. Guo. (2022) Safety and cost-effectiveness of ponatinib versus other tyrosine kinase inhibitors as second-line therapy in patients with chronic myeloid leukemia in the United States. Leukemia & Lymphoma 63:4, pages 946-954.
Read now
Read now
Elias J. Jabbour, Martin F. Mendiola, Melissa Lingohr-Smith, Jay Lin & Dinara Makenbaeva. (2019) Economic modeling to evaluate the impact of chronic myeloid leukemia therapy management on the oncology care model in the US. Journal of Medical Economics 22:11, pages 1113-1118.
Read now
Read now
Elias J. Jabbour, Lisa R. Siegartel, Jay Lin, Melissa Lingohr-Smith, Brandy Menges & Dinara Makenbaeva. (2019) Impact of earlier versus later monitoring on disease progression and healthcare costs among patients with chronic myeloid leukemia in the United States. Leukemia & Lymphoma 60:3, pages 668-674.
Read now
Read now
Elias J. Jabbour, Lisa R. Siegartel, Jay Lin, Melissa Lingohr-Smith, Brandy Menges & Dinara Makenbaeva. (2018) Economic value of regular monitoring of response to treatment among US patients with chronic myeloid leukemia based on an economic model. Journal of Medical Economics 21:10, pages 1036-1040.
Read now
Read now
Ahmet Emre Eskazan. (2018) The issue of financial toxicity in the management of chronic myeloid leukemia with blast crisis. Journal of Medical Economics 21:7, pages 709-711.
Read now
Read now
Articles from other publishers (6)
Massimo Breccia, Francesca Chiodi, Aurelio Pio Nardozza, Diletta Valsecchi, Valentina Perrone, Diego Sangiorgi, Elisa Giacomini, Maria Chiara Rendace, Paola Coco, Eleonora Premoli & Luca Degli Esposti. (2022) The Economic Burden of Chronic Myeloid Leukemia in Patients with Later Lines: Findings from a Real-World Analysis in Italy. Advances in Therapy 40:3, pages 961-974.
Crossref
Crossref
Ehab L. Atallah, Rodrigo Maegawa, Dominick Latremouille-Viau, Carmine Rossi & Annie Guérin. (2022) Chronic Myeloid Leukemia: Part II—Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective. Journal of Health Economics and Outcomes Research 9:2.
Crossref
Crossref
Ehab Atallah, Rodrigo Maegawa, Dominick Latremouille-Viau, Carmine Rossi & Annie Guérin. (2022) Chronic Myeloid Leukemia: Part II—Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective. Journal of Health Economics and Outcomes Research 9:2, pages 30-36.
Crossref
Crossref
Fabrizio Angaroni, Alex Graudenzi, Marco Rossignolo, Davide Maspero, Tommaso Calarco, Rocco Piazza, Simone Montangero & Marco Antoniotti. (2020) An Optimal Control Framework for the Automated Design of Personalized Cancer Treatments. Frontiers in Bioengineering and Biotechnology 8.
Crossref
Crossref
Kelly M. Kenzik, Ravi Bhatia, Grant R. Williams & Smita Bhatia. (2019) Medicare and patient spending among beneficiaries diagnosed with chronic myelogenous leukemia. Cancer.
Crossref
Crossref
Atsushi Ogasawara, Hiromichi Matsushita, Yumiko Tanaka, Yukari Shirasugi, Kiyoshi Ando, Satomi Asai & Hayato Miyachi. (2019) A simple screening method for the diagnosis of chronic myeloid leukemia using the parameters of a complete blood count and differentials. Clinica Chimica Acta 489, pages 249-253.
Crossref
Crossref